Sports injuries, which commonly affect bones, muscles, tendons, ligaments and cartilage, result from participation in competitive sports, exercise or other athletic activities. If you have experienced an acute (sudden) or chronic (developed over time) sports injury, we understand your desire to get “back in the game” as quickly as possible. Depending on the exact nature of your injury, stem cell therapy might help you heal faster and potentially avoid invasive surgery.
Human umbilical cord tissue-derived mesenchymal stem cells (hUCT-MSCs), like the Golden Cells™ we use at Stem Cell Institute are well known for promoting healing, reducing inflammation and promoting tissue growth, all of which are important factors for healing many types of sports injuries like Achilles tendonitis, sprains and strains, ACL/MCL tears, rotator cuff tears, tennis elbow, and runner’s knee.
A peer-reviewed article published in 2020 by S Trebinjac and M Gharairi entitled, Mesenchymal Stem Cells for Treatment of Tendon and Ligament Injuries-clinical Evidence, concluded that: “Clinical application of MSCs for treatment of tendon and ligament injuries might be good alternative option for athletes. Published clinical studies confirmed clinical improvement and integrity of impaired tissues…”
“Neil takes readers on a riveting journey through the past, present, and future of stem cell therapy. His well-researched, educational, and entertaining book could change your life. I highly recommend it.”
– Tony Robbins, NY Times #1 Bestselling Author
My general quality of life has 100% gotten better. Just start [the process] now.
No need to collect stem cells from the patient’s hip bone or fat under anesthesia, which can be an unpleasant ordeal.
There is a growing body of evidence showing that umbilical cord tissue-derived (HUCT) mesenchymal stem cells are more robust than mesenchymal stem cells from other sources.
No need to administer chemotherapy drugs like granulocyte-colony stimulating factor (G-CSF or GCSF) to stimulate the bone marrow to produce granulocytes and stem cells, and release them into the bloodstream.
Since HUCT mesenchymal stem cells are immune system privileged, cell rejection is not an issue and Human Leukocyte Antigen (HLA) matching is not necessary.
The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened and selected.
Allogeneic stem cells can be administered multiple times over the course of days in uniform dosages that contain high cell counts.
Umbilical cord tissue provides an abundant supply of mesenchymal stem cells.
We use Golden Cells™. Years-long retrospective analysis of patient outcomes has enabled us to identify and select the best cells for use in our patients.
One of our physicians will assign a stem cell treatment protocol after you have submitted all requested medical information and received approval. Your recommended protocol may differ from the example given below:
Note: Includes Hilton hotel room with breakfast, WIFI, transportation from and to the airport with VIP airport gate service and expedited customs clearance upon arrival.
No stem cell product from any source, including the patient’s own, is approved by the US FDA to treat sports injuries.
However, human umbilical cord tissue-derived mesenchymal stem cells that were isolated and grown in our laboratory in Panama to create master cell banks have been used in the United States under US FDA regulation.
These cells served as the starting material for cellular products used in MSC clinical trials for two Duchenne’s muscular dystrophy patients under US FDA’s designation of Investigational New Drug (IND) for single-patient compassionate use. (IND 16026 DMD Single Patient).
The body’s immune system is unable to recognize umbilical cord-derived mesenchymal stem cells as foreign, and therefore they are not rejected. Human umbilical cord tissue stem cells have been administered tens of thousands of times at the Stem Cell Institute, and there has never been a single instance of rejection (graft vs. host disease). As a matter of fact, allogeneic (not the patient’s own) mesenchymal stem cells are approved to treat graft vs. host disease in Canada and New Zealand.
Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than “older” cells, such as those found in the fat, and therefore, they are considered to be more “potent”.
The adult stem cells used to treat sports injuries at the Stem Cell Institute come from human umbilical cord tissue (allogeneic mesenchymal). These stem cells are expanded at Medistem Panama’s state-of-the-art laboratory.
The mesenchymal stem cells we use are recovered from donated umbilical cords following normal, healthy births. Each mother has her medical history screened and is tested for infectious diseases. Proper consent is received from each family prior to donation.
All umbilical cord-derived stem cells are screened for infectious diseases to International Blood Bank Standards before they are cleared for use in patients.
Only a small percentage of donated umbilical cords pass our rigorous screening process.
Proper follow-up is an essential part of stem cell therapy. Our primary goal is to ensure that you are progressing safely. Regular follow-up also enables us to evaluate efficacy and improve our treatment protocols based on observed outcomes.
Therefore, our medical staff will be contacting you after 1 month, 3 months, 6 months, 9 months, and 1 year to monitor your child’s progress.
You can apply today to find out if you are eligible for treatment. You may also contact us by telephone 1 (800) 980-7836 (toll-free in US) and 1 (954) 358-3382 (International).
Toll Free:
1-800-980-STEM (7836)
Outside or Inside US Call:
1-954-358-3382
Toll Free Fax (US Only):
1-866-755-3951
From Outside US Fax:
1-775-887-1194
Copyright 2024, Stem Cell Insitute Panama. All rights reserved.